News

Wired7h
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
According to its creator, Gilead Sciences, lenacapavir will be marketed under the trade name Yeztugo. The company has committed to manufacturing 10 million doses by 2026. “This is a historic day ...
Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
Fierce Pharma1d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
The BMJ3h
“Hard to justify” $28 000 price tag for breakthrough HIV prevention treatment, says UN agency
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
Should You Buy Gilead Stock At $110?
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
CSRWire1d
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award
Gilead has been a leader in HIV innovation for decades. Now, we're proud to share that one of our researchers, Moupali Das, ...